Presentations and films

CPL’36 Unlocking New Possibilities in LiDTreatment – Phase 2 Top-Line Results

Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL’36)

Investor's teleconference Y2022

Presentation Q3 2022

Corporate movie

Investor's teleconference 1Q 2022

Investor Day 2022

Investor's teleconference

Capital Markets Day - 21.04.2021

Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression

Shareholders of Celon Pharma S.A. On February 16, 2021, they will decide to authorize the Management Board to increase the share capital within the authorized capital by issuing new shares.